|3.||Head and Neck Neoplasms (Head and Neck Cancer)
|1.||Gibson, Rachel J: 37 articles (11/2015 - 07/2002)|
|2.||Bowen, Joanne M: 28 articles (07/2015 - 09/2005)|
|3.||Howarth, Gordon S: 28 articles (01/2015 - 05/2003)|
|4.||Keefe, Dorothy M K: 25 articles (01/2010 - 07/2002)|
|5.||Stringer, Andrea M: 24 articles (07/2015 - 01/2007)|
|6.||Sonis, Stephen T: 23 articles (01/2013 - 01/2002)|
|7.||Butler, Ross N: 20 articles (12/2012 - 05/2003)|
|8.||Epstein, Joel B: 18 articles (11/2013 - 07/2002)|
|9.||Logan, Richard M: 17 articles (07/2015 - 01/2007)|
|10.||Keefe, Dorothy M: 15 articles (11/2015 - 06/2006)|
|1.||Amifostine (Ethyol)FDA LinkGeneric
07/01/2000 - "The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0. "
06/01/2000 - "A significant reduction of pharyngeal, esophageal, and rectal mucositis was noted in the amifostine arm (P <.04). "
06/01/1986 - "We have previously reported that Amifostine, a radioprotective agent, was effective in treating acute radiation mucositis in the head and neck region. "
01/01/2002 - "The authors have developed a rat RT model to examine the protective effects of amifostine after IV and subcutaneous (SC) administration in a mucositis model. "
03/01/2002 - "Ongoing trials are being conducted to determine the efficacy of amifostine in reducing radiation-induced mucositis and other toxicities. "
|2.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/01/2005 - "Forty-five percent of the patients randomized to receive GM-CSF had a significant reduction of the mucositis more than one grade compared to 9% of the conventional treated. "
01/01/2005 - "In severe mucositis, GM-CSF is more effective than conventional treatment."
03/01/2006 - "The present study was performed to investigate the protective effects of granulocyte macrophage-colony stimulating factor (GM-CSF) against ulcerative mucositis in hamster buccal pouch. "
01/01/2005 - "This trial examined the efficacy of GM-CSF in reducing mucositis of the oral cavity and/or oropharynx compared with conventional treatment. "
02/01/2000 - "We found no evidence indicating that subcutaneously given GM-CSF reduces the severity of radiation-induced mucositis."
|3.||Fluorouracil (Carac)FDA LinkGeneric
02/15/1995 - "A Grade II mucositis, according to the World Health Organization, was found in 25 patients, and the treatment was interrupted for 7-10 days in 5. In this study, despite an improvement in the number of complete responses, the chemotherapeutic regimen with or without 5-FU did not prolong the overall patient survival significantly."
03/01/2015 - "This study aimed to evaluate the beneficial effects of Bifidobacterium infantis in a rat model of intestinal mucositis induced by 5-fluorouracil (5-FU). "
12/01/2014 - "Therefore, the present study aimed to test the ability of hUP blockers in preventing mucositis induced by 5-FU. "
09/01/2011 - "This study evaluated the role of PAF in 5-fluorouracil (5-FU)-induced intestinal mucositis using a pharmacological approach and PAF receptor knockout mice (PAFR(-/-)). "
07/01/2010 - "Although 5-FU is considered to exert significant stomatotoxic effect, severe mucositis was far less common in this study compared to studies reported elsewhere."
|4.||Glutamine (L-Glutamine)FDA Link
01/01/2015 - "In our group, a statistically significant reduction in the duration of mucositis was observed in patients who received parenteral glutamine. "
10/01/2005 - "Glutamine appears to be safe and beneficial in reducing the severity of mucositis. "
06/27/2011 - "Intravenous glutamine-enriched solution seems to be effective in posttransplant period in decreasing the severity and duration of mucositis. "
01/01/2015 - "The present study investigated whether L-glutamine (glutamine) decreases the severity of mucositis in the oral cavity, pharynx and larynx induced by CRT. "
01/01/2014 - "Grade 3 mucositis (14.29%) and grade 4 mucositis (2.86%) in the study arm (who received oral glutamine) were significantly less (P = 0.02 and P = 0.04, respectively) in the glutamine arm. "
|5.||Sucralfate (Carafate)FDA LinkGeneric
01/01/1999 - "Sucralfate mouth washing is beneficial in decreasing the intensity of radiation-induced mucositis and oral discomfort. "
07/01/2001 - "In this double blind randomised study, we tested the efficacy of sucralfate for the prevention of mucositis induced by such conditioning treatments. "
01/01/1995 - "There is increasing evidence that sucralfate reduces the severity of radiation-induced mucositis in the head and neck, esophagus, and the lower gastrointestinal tract. "
01/01/2003 - "Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial."
03/01/1997 - "There was a total of 131 assessable patients entered onto this trial, 50 of whom developed mucositis and used the study medication (27 sucralfate and 23 placebo). "
|6.||irinotecan (Camptosar)FDA LinkGeneric
01/01/2016 - "We investigated in a rat model whether SBI was effective in alleviating symptoms of irinotecan-induced GI mucositis. "
01/01/2015 - "This study shows a critical role of the MyD88-mediated TLR2 and TLR9 signaling in the pathogenesis of irinotecan-induced intestinal mucositis. "
07/01/2014 - "This study assessed mechanisms and the role of inflammasome activation in irinotecan-induced mucositis. "
01/01/2011 - "For normalisation of irinotecan-induced mucositis gene expression studies, a combination of Ywhaz/UBC and UBC/β-actin should be used in the jejunum and colon, respectively. "
01/01/2011 - "As this method relies on the use of a validated endogenous control, this study aims to validate commonly used housekeeping genes in an irinotecan-induced mucositis model. "
05/01/2004 - "According to this sequential analysis, the study could be terminated at the 34th within subject comparison, with a statistically significant reduction in ulcerative lesions (P<0.05) and severity of mucositis (P<0.05) in children on the chlorhexidine protocol. "
02/01/2013 - "Chlorhexidine 0.2% mouthwash and chlorhexidine 1% gel were equally useful in the treatment of peri-implant mucositis leading to the reduction in inflammatory parameters. "
01/01/2015 - "The aim of our study was to assess the efficacy of Octenidol(®), Glandomed(®) and chlorhexidine mouthwash in the prevention of mucositis and reduction of the oropharyngeal flora. "
12/01/1994 - "Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis."
01/01/2015 - "The role of Octenidol(®), Glandomed(®) and chlorhexidine mouthwash in the prevention of mucositis and in the reduction of the oropharyngeal flora: a double-blind randomized controlled trial."
09/01/2012 - "A significant reduction in mucositis in honey-received patients compared with 0.15% benzydamine hydrochloride, 0.9% normal saline applied patients occurred. "
03/01/2009 - "We evaluated the efficacy of benzydamine oral rinse for prevention of radiation-induced mucositis. "
01/01/1985 - "A double-blind, randomized clinical study was undertaken to determine the analgesic and antiinflammatory effectiveness of benzydamine in patients with radiation-induced mucositis of the oropharynx. "
01/01/2015 - "Aloe vera mouthwash was as beneficial as benzydamine mouthwash in alleviating the severity of radiation-induced mucositis and showed no side effects. "
01/01/2015 - "The mean interval between the start of radiation therapy and the maximum severity of mucositis were was also similar in both the Aloe vera and benzydamine groups (Aloe vera 23.38±10.75 days, benzydamine 23.54±15.45 days). "
|9.||Fibroblast Growth Factor 7FDA Link
06/01/2009 - "Palifermin is a recombinant keratinocyte growth factor that has been shown to be effective in decreasing the incidence, severity and duration of mucositis in Phase III trials. "
12/01/2011 - "Furthermore, we additionally amended supportive care with palifermin as it reduced severity and prevalence of mucositis ."
09/01/2011 - "Further studies are indicated to investigate the prophylactic potential of palifermin against intestinal mucositis."
05/20/2008 - "Future studies should evaluate higher palifermin doses with longer and more standardized assessment of acute mucositis."
07/01/2007 - "In clinical trials, palifermin, a recombinant humanized keratinocyte growth factor (rHuKGF), has demonstrated an ability to decrease the incidence and duration of mucositis. "
|10.||Cisplatin (Platino)FDA LinkGeneric
01/01/2013 - "Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats."
01/01/2008 - "The most common acute toxicity of Cisplatin plus RT was grade 3-4 mucositis (64%). "
02/01/1994 - "Severe and worse toxic events were similar between the treatment programs, but radiation-induced mucositis combined with cisplatin-induced water-losing nephropathy, in the concomitant arm only, demanded more supportive care. "
04/01/2007 - "Although therapeutics results are equivalent to cisplatin schemes of concurrent CT-RT, mucositis and cutaneous toxicity registered in this trial must be considered as limiting factors to application of this new approach."
08/01/2004 - "Toxicities of cisplatin chemoradiotherapy consisted of grade 3 or 4 mucositis (79%) and neutropenia (51%). "
|1.||Drug Therapy (Chemotherapy)
04/01/2009 - "The BIQAC had the most braod-spectrum radical scavenging activity, suggesting that it may be effective against chemotherapy-induced mucositis. "
10/01/2013 - "Chemotherapy-induced mucositis represents a significant burden to quality of life and healthcare costs, and may be improved through enhanced nutritional status. "
10/01/2002 - "Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown."
02/01/1999 - "In the Gln group, a significant reduction in mucositis and ulcerations of the gastric (P < 0.01) and duodenal mucosa (P < 0.05) was documented after the third course of chemotherapy. "
08/01/2015 - "ED may possibly be more effective for the prevention of antineoplastic chemotherapy-induced mucositis through the activation of GI mucus cells."
01/01/2006 - "A significant reduction of severe mucositis at the end of radiotherapy (14.7 vs 44.8%, p=0.018) and of interruptions (0 vs 17.2%, p=0.017) was observed in group A. "
02/01/2016 - "The present study was designed to evaluate the preventive effects of elemental diet (ED), Elental®, on radiotherapy- or chemoradiotherapy-induced mucositis in OSCC patients. "
06/01/2015 - "The study found that performance status, pre-RT haemoglobin level, radiotherapy interruptions > 5 days and non-development of grade III mucositis was found to be significantly associated with good loco-regional control. "
04/01/2012 - "This study evaluated the effects of administering Lactobacillus brevis CD2 lozenges on the incidence and severity of mucositis and tolerance to chemo-radiotherapy. "
10/01/2002 - "The primary end point of the study was the time to development of severe mucositis from the start of radiotherapy. "
|3.||Oral Hygiene (Dental Hygiene)
11/01/1985 - "A nonbrushing method of oral hygiene was effective in reducing the severity and duration of mucositis. "
11/01/2006 - "In our study, a good gingival status as well as good oral hygiene during chemoradiotherapy is associated with a lower incidence and severity of mucositis."
11/01/2006 - "A descriptive study was made, analyzing oral hygiene, one dental index, and two gingivales indices, and evaluating their relationship with the appearance of mucositis. "
01/01/1999 - "The purposes of this study were to determine if there were differences in the incidence, severity, and time to onset of CTX-induced mucositis in oncology outpatients who wore dental appliances, had a history of oral lesions, had varying oral hygiene/care practices, and had a history of smoking and those who did not. "
01/01/2000 - "Basic requirements in prevention and control of mucositis are good oral hygiene, mechanical débridement of the oral tissues, and hydration."
|4.||Cryotherapy (Therapy, Cold)
08/01/2010 - "Oral cryotherapy reduces mucositis and improves nutrition - a randomised controlled trial."
09/01/2012 - "We found that oral cryotherapy has a significant contribution to the protection of oral health by reducing mucositis score according to the WHO mucositis scale, especially on the 7th and 14th days. "
10/01/2007 - "Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial."
06/01/2006 - "Compared to the normal saline group, patients using cryotherapy experienced less grade 3-4 mucositis, 14 vs 74%, P=0.0005. "
07/01/2005 - "Our findings have demonstrated that oral cryotherapy makes an important contribution to the protection of oral health by reducing the mucositis score according to patient- and physician-judged mucositis score and by increasing oral pH values. "
|5.||Low-Level Laser Therapy (LLLT)
08/01/2010 - "This study supports two mechanisms of action for LLLT in reducing mucositis severity. "
11/01/2015 - "Clinical mucositis scores were significantly lower in the LLLT group than in the control group (p = 0.004). "
06/01/2015 - "Prophylactic LLLT reduced the overall risk of severe mucositis (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.20 to 0.67; P = 0.001). "
01/01/2014 - "Prophylactic LLLT reduced the overall risk of severe mucositis (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.20 to 0.67; P = 0.001). "
01/01/2014 - "Objective was to determine whether prophylactic low level laser therapy (LLLT) reduces the risk of severe mucositis as compared to placebo or no therapy. "